DEPAZIDE-GM2 TABLETS | DAPAGLIFLOZIN 10MG + GLIMPRIDE 2MG + METFORMIN 500MG TABLETS

DEPAZIDE-GM2 is an advanced triple combination therapy designed to provide comprehensive glycemic control in adults with Type 2 Diabetes Mellitus (T2DM). This formulation harnesses the complementary actions of three well-established antidiabetic agents — Dapagliflozin, Glimepiride, and Metformin — to target multiple pathophysiological defects of diabetes.

Pharmacological Actions and Mechanism

Dapagliflozin (10 mg)

Belongs to the class of Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors.

Acts by blocking renal glucose reabsorption in the proximal renal tubules, leading to increased urinary glucose excretion.

Promotes modest weight reduction and mild blood pressure lowering.

Functions independently of insulin, minimizing the risk of hypoglycemia.

2. Glimepiride (2 mg)

A second-generation sulfonylurea that enhances pancreatic β-cell insulin secretion.

Reduces both fasting and postprandial glucose levels.

Demonstrates long-lasting glycemic control and proven efficacy in combination regimens.

3. Metformin (500 mg, Sustained Release)

A biguanide that decreases hepatic glucose production (gluconeogenesis).

Improves peripheral insulin sensitivity and glucose uptake in muscles.

Has favorable effects on lipid profile, weight management, and cardiovascular outcomes.

DEPAZIDE-GM2 Tablets are indicated for

The management of Type 2 Diabetes Mellitus in adults, particularly when monotherapy or dual therapy fails to achieve adequate glycemic control.
Patients requiring combination therapy to achieve optimal HbA1c reduction.
As part of an overall treatment plan including diet control and regular physical activity.